Targets › GP120
2 programs from 2 companies in 7 trials: 3 Phase 1, 2 Phase 3, 1 Phase 4, 1 Phase 2; Infectious disease; next expected readout Jan 2027.
Open in Phaseline: the race on GP120, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Fostemsavir Envelope polyprotein GP160 inhibitor | INSTI, GP120, CD4 | Phase 3 | HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant Virus | Jan 2027 |
| Steven Deeks | LVgp120duoCAR-T cells CAR-T cells expressing dual CAR targeting gp120, the envelope glycoprotein of HIV | GP120, ENV | Phase 1 | HIV Infections | Dec 2028 |
HIV Infections (4) HIV-1-infection (1) Human Immunodeficiency Virus (HIV) (1) HIV Infections With Multi Drug Resistant Virus (1)
mixed (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.